

# Sarcomatrix Acquires Recombinant Human Laminin-111: A Promising Candidate for Treating LAMA2-RD Muscular Dystrophies

*Recombinant human laminin-111, often referred to as rLaminin-111, mimics the natural laminin-alpha-2 protein found in healthy muscle tissue.*

**SARCOMATRIX**  
Saving Lives by Restoring Muscles

RENO, NV, UNITED STATES, May 10, 2024 /EINPresswire.com/ -- Sarcomatrix Therapeutics Corp., a leader in biopharmaceutical innovations, is thrilled to announce the acquisition of a promising new therapy, rhLaminin-111, aimed at treating LAMA2-Related Dystrophies, a rare and life-threatening genetic disorder. This acquisition from Prothelia, Inc. positions Sarcomatrix at the forefront of [muscular dystrophy](#) research.

“

With funding we can advance laminin-111 to first-in-human trials in 2024, this year.”

*David Craig, CEO*

The portfolio of intellectual property acquired includes an extensive worldwide patent portfolio, an optimized and proprietary manufacturing process, quality control procedures, clinical development plan, regulatory filing strategy, and extensive pre-clinical data on a variety of animal, cell and in silico models.

LAMA2-Related Dystrophies severely impair respiratory functions, muscle tone, and motor skills development among affected children, also leading to complications such as muscle atrophy, scoliosis, and joint issues. The investigational preclinical studies of Laminin-111 are underway, promising a first-in-class protein replacement therapy that could transform patient outcomes.

Dr. Ryan Wuebbles, Chief Science Officer and Global Head of Discovery Research at Sarcomatrix, expressed his enthusiasm: "With the integration of Laminin-111 into our portfolio, we not only expand our research capabilities but also reinforce our commitment to addressing [muscle wasting](#) conditions, including muscular dystrophies. This strategic acquisition enables us to enhance and potentially accelerate our efforts to meet urgent medical needs."

Sarcomatrix is dedicated to advancing this potential treatment through critical pre-clinical studies and aims to initiate human trials as promptly as feasibility allows. The company is actively seeking additional funding to propel these efforts forward.

## About Sarcomatrix Therapeutics Corp.

At Sarcomatrix, we harness the power of science to develop therapies that extend and significantly enhance lives. We are committed to leading the way in quality, safety, and value in the discovery and development of groundbreaking medicines. Our mission has been to make a meaningful impact on everyone who depends on us. We regularly update our website with information vital to investors at [www.Sarcomatrix.com](http://www.Sarcomatrix.com). Additionally, to discover more, please visit us at [www.Sarcomatrix.com](http://www.Sarcomatrix.com) and follow us on X at @Sarcomatrix and @Sarcomatrix News, LinkedIn/company/sarcomatrix YouTube, and Facebook at <https://www.facebook.com/sarcomatrix>.

## Support Sarcomatrix

Sarcomatrix has launched an equity crowdfunding campaign on StartEngine, go to <https://www.startengine.com/offering/sarcomatrix> to find out more. Our business initiative is designed to accelerate the development of our promising drug treatments for muscle diseases. We are inviting investors to participate in joining our team, which seeks to drive advancements in medical treatments for conditions that impact millions. Join us in shaping the future of muscle disease therapy and explore the potential of becoming part of a community dedicated to healthcare innovation.

### Media Contact:

MediaRelations@Sarcomatrix.com  
+1 (775) 525-1795

### Investor Contact:

IR@Sarcomatrix.com

Source: Sarcomatrix® Therapeutics, Corp.

David Craig  
Sarcomatrix, Inc.  
+1 415-246-3311  
David Craig

David Craig  
Sarcomatrix, Inc.  
+1 415-246-3311

[email us here](#)

Visit us on social media:

[Facebook](#)

Twitter  
LinkedIn  
Instagram  
YouTube  
TikTok

---

This press release can be viewed online at: <https://www.einpresswire.com/article/710495048>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.